AbbVie Inc. (ABBV)
Is AbbVie a Buy, Sell, or Hold in 2026?
AbbVie's guidance for the next few years implies robust revenue growth. Some of the company's products are performing even better than expected.
The Zacks Analyst Blog AbbVie, The Coca-Cola, Chevron, ImmuCell and Precipio
AbbVie headlines today's top stock reports as Zacks highlights pharma recovery, resilient beverages and Chevron???s evolving energy outlook.
ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
5 Big Drug Stocks That May Continue to Outperform in 2026
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
How AbbVie's Pipeline Is Lining Up Key Product Launches
ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.
5 Dividend Powerhouses That Could Transform Your Portfolio Into a Wealth-Building Machine
Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals.
AbbVie Slipped Below 50-Day SMA Last Week: How to Play the Stock
AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.
Proven Income Generators: Ranking the Most Reliable Dividend Growth Stocks
Dividend investing rewards patience. The best dividend stocks don't just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course.
Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul
The wall of worry continues to grow as investors race into 2026. Concentration risk is one that may not get talked about enough.
Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth
ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.
AbbVie: Unique Mix Of Growth And Value
AbbVie earns a Strong Buy rating, driven by exceptional execution post-Humira patent cliff and robust 2025 share price outperformance. Skyrizi and Rinvoq are rapidly replacing Humira, delivering 47% and 35% YoY growth in Q3 2025, with patent protection into the 2030s. ABBV's business mix is diversified, with immunology and neuroscience segments together driving double-digit revenue growth and supporting strong EPS prospects.
